- Investment firm Baker Bros. Advisors profited $US730 million Monday after its stake in Seattle Genetics soared on positive drug news, according to Bloomberg data.
- The biotech company’s tucatinib treatment surpassed expectations in a recent breast cancer study and improved the condition for patients whose cancer had reached their brains, the company said.
- Baker Bros. held a 29% stake in the company as of June 30, a position now worth about $US5 billion after the positive drug news.
- Watch Seattle Genetics trade live here.
Seattle Genetics traded as much as 18% higher Monday after a breast cancer study found its tucatinib treatment successfully countered the spread of cancer cells. The treatment posted better-than-expected improvements for patients whose cancer had reached their brains, the company said in a release.
Baker Bros. held a 29% stake in the biotech company as of June 30, according to Bloomberg, a position worth about $US5 billion after the positive drug news. Seattle Genetics is the firm’s largest holding.
Seattle Genetics stock is up roughly 79% year-to-date. Its Monday peak of $US101.95 per share was a record high for the stock.
The biotech company has 12 “buy” ratings, five “hold” ratings, and one “sell” rating, with a consensus price target of $US90.13, according to Bloomberg data.
The company’s consensus price target jumped nearly 5% after Monday’s news prompted a series of upgrades.
Now read more markets coverage from Markets Insider and Business Insider:
Business Insider Emails & Alerts
Site highlights each day to your inbox.